Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. [electronic resource]
Producer: 20191028Description: 1266-1272 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- pharmacology
- Antigens, CD19 -- immunology
- Antineoplastic Agents, Immunological -- pharmacology
- Drug Resistance, Neoplasm -- drug effects
- Female
- Humans
- Injection Site Reaction -- epidemiology
- Lymphoma, B-Cell -- drug therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neutropenia -- chemically induced
- Progression-Free Survival
- Rituximab -- pharmacology
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.